Logo
홈페이지
모델 살펴보기
장바구니
연락처
구독하기
연구 모델
HUGO Series 🌟
HUGO-GT™(유전자 치료를 위한 인간화 게놈 Ortholog)
HUGO-Ab™(항체 개발을 위한 인간화 게놈 Ortholog)
MouseAtlas 모델 라이브러리
번개 세일
연구용 동물 모델
Cre 마우스
인간화 타겟 유전자 모델
대사 질환 모델
안과 질환 모델
신경질환 모델
자가면역 질환 모델
면역결핍 마우스 모델
인간화 면역계 마우스 모델
종양 및 면역 항암 모델
Covid-19 마우스 모델
세포주 모델
Knockout 세포주 제품 카탈로그
종양 세포주 제품 카탈로그
유도만능줄기세포(iPSC) 카탈로그
AAV 표준 제품 카탈로그
서비스
전임상 효능 평가
신경과학
알츠하이머병(AD)
혈액-뇌 장벽(BBB)
파킨슨병(PD)
헌팅턴병(HD)
안과학
녹내장
연령관련 황반변성(AMD)
종양학
PBMC 인간화 마우스 모델
면역항암 연구를 위한 인간 면역 시스템(HIS) 마우스
대사 및 심혈관 질환
자가면역 및 염증
유전자 변형 동물
Knockout 마우스
Transgenic 마우스
Knock-in 마우스
Knockout Rat
Knock-in(KI) Rat
Transgenic Rat
모델 제작 기술
Turboknockout™ 유전자 타겟팅
타겟 유전자 편집
일반 Transgenic
PiggyBac Transgenesis
BAC Transgenic
ES 세포 유전자 타겟팅
브리딩 및 지원 서비스
브리딩 서비스
동결 보존 및 복원
Phenotyping 서비스
BAC 변형 서비스
바이러스 패키징
AAV 패키징
렌티바이러스(Lentivirus) 패키징
아데노바이러스(Adenovirus ) 패키징
맞춤형 세포주 서비스
유도만능줄기세포(iPSCs)
Knockout(KO) 세포주
Knock-in(KI) 세포주
Point Mutation 세포주
과발현 세포주
모달리티
유전자 치료
AI 기반 AAV 발굴
Oligonucleotide 치료
세포 면역치료
Resource
프로모션
이벤트 및 웨비나
뉴스
블로그 및 인사이트
자료실
참고 데이터베이스
Peer-Reviewed 인용
희귀질환 데이터센터
AbSeek
Cell iGeneEditor™ System
OriCell 세포 배양
회사 소개
회사 소개
시설 개요
동물 건강 및 복지
건강 보고서
대리점
인재채용
문의하기
Login
필터
필터
KO/cKO Mouse Models
Flash Sales
HUGO-GT™ Platform
Full-Gene Humanized Models
Humanized Target Gene Models
Immune Target Humanized ModelsTumor Target Humanized ModelsMetabolic Target Humanized ModelsCytokine Humanized ModelsOther Target Humanized Models
Immune System Mouse Models
Immunodeficient Mouse ModelsHumanized Immune System Models
Genetic Tool Mouse Models
Cre Driver LinesReporter Mouse LinesOther Genetic Tool Lines
Specialized Disease Models
Ophthalmic Disease ModelsNeurological Disease ModelsMetabolic Disease ModelsOncology & Immuno-oncology ModelsAutoimmune Disease ModelsRare Disease ModelsInfectious Disease ModelsOther Disease Models
“6336” 에 대한 검색 결과 2 건
필터
정렬 기준:
알파벳순 (A-Z)
베스트셀러
hSCN10A(Nav1.8)(SD)
제품 ID:
CR006
계통(Strain):
SD
상태:
Live Mouse
설명:
The SCN10A gene, which encodes the sodium channel Na(v)1.8, is a susceptibility factor for cardiac conduction block and severe ventricular arrhythmias. Genetic variations in ion channel genes are associated with hereditary arrhythmias, such as Long QT Syndrome, Short QT Syndrome, Brugada Syndrome (BrS), and conduction abnormalities. These variations are also linked to sudden unexplained death (SUD) in young adults and children. Several studies have identified common variants of SCN10A as potential regulators of human PR and QRS durations, with SCN10A being a major susceptibility gene for BrS [1-2]. The Nav1.8 protein is expressed in small-diameter sensory neurons of the trigeminal ganglion and dorsal root ganglion (DRG), as well as in some medium- and large-diameter neurons and in layers I and II of the spinal dorsal horn [3]. The SCN10A/Nav1.8 voltage-gated sodium channel is crucial in pain management. Studies have shown that Nav1.8 channel inhibitors have the potential to become a new class of effective analgesics suitable for multimodal pain treatment in postoperative patients. Additionally, the low expression of SCN10A in the brain suggests a lower likelihood of adverse effects, including dependency and abuse, within the central nervous system [4]. In early 2025, the FDA approved Suzetrigine, a Nav1.8 inhibitor developed by Vertex Pharmaceuticals, marking a breakthrough in the pain management field previously dominated by opioid drugs. As the first non-opioid acute pain medication in two decades, the success of Suzetrigine is a significant milestone. hSCN10A(Nav1.8)(SD) rats are a Scn10a humanized model created by inserting the human SCN10A gene's coding sequence (CDS) and 3'UTR into the rat Scn10a gene. This model can be used for mechanistic studies of acute pain and diabetic peripheral neuropathic pain and the development, screening, and evaluation of analgesic drugs in preclinical research. During the production of this rat strain, scratching behavior was observed after weaning and cage separation, resulting in skin lesions. Trimming the nails at the time of cage separation effectively prevents such skin damage. For long-term prevention, nail trimming should be repeated every 2 weeks.
The SCN10A gene, which encodes the sodium channel Na(v)1.8, is a susceptibility factor for cardiac conduction block and severe ventricular arrhythmias. Genetic variations in ion channel genes are associated with hereditary arrhythmias, such as Long QT Syndrome, Short QT Syndrome, Brugada Syndrome (BrS), and conduction abnormalities. These variations are also linked to sudden unexplained death (SUD) in young adults and children. Several studies have identified common variants of SCN10A as potential regulators of human PR and QRS durations, with SCN10A being a major susceptibility gene for BrS [1-2]. The Nav1.8 protein is expressed in small-diameter sensory neurons of the trigeminal ganglion and dorsal root ganglion (DRG), as well as in some medium- and large-diameter neurons and in layers I and II of the spinal dorsal horn [3]. The SCN10A/Nav1.8 voltage-gated sodium channel is crucial in pain management. Studies have shown that Nav1.8 channel inhibitors have the potential to become a new class of effective analgesics suitable for multimodal pain treatment in postoperative patients. Additionally, the low expression of SCN10A in the brain suggests a lower likelihood of adverse effects, including dependency and abuse, within the central nervous system [4]. In early 2025, the FDA approved Suzetrigine, a Nav1.8 inhibitor developed by Vertex Pharmaceuticals, marking a breakthrough in the pain management field previously dominated by opioid drugs. As the first non-opioid acute pain medication in two decades, the success of Suzetrigine is a significant milestone. hSCN10A(Nav1.8)(SD) rats are a Scn10a humanized model created by inserting the human SCN10A gene's coding sequence (CDS) and 3'UTR into the rat Scn10a gene. This model can be used for mechanistic studies of acute pain and diabetic peripheral neuropathic pain and the development, screening, and evaluation of analgesic drugs in preclinical research. During the production of this rat strain, scratching behavior was observed after weaning and cage separation, resulting in skin lesions. Trimming the nails at the time of cage separation effectively prevents such skin damage. For long-term prevention, nail trimming should be repeated every 2 weeks.
Pars2-KO
제품 ID:
S-KO-06336
계통(Strain):
C57BL/6JCya
상태:
Research and Development
설명:
Pars2 is located on chromosome 4 of mice. Nuclease Technology will be used to design sgRNA; Pars2 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Pars2 is located on chromosome 4 of mice. Nuclease Technology will be used to design sgRNA; Pars2 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Items: 1 to 2 of 2
1
더보기
전체 필터
Strain Type
Mouse
Rat
Modification Type
Knockout
Conditional Knockout
Knockin
Point Mutation
Transgenic
Conditional Knockin
Others
Status
Live Mice
R&D
Frozen Sperm
Validation Data
Verified
In Progress
초기화
확인
모델 라이브러리
모델 라이브러리
리소스
리소스
동물 품질
동물 품질
고객 지원
고객 지원
주소:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
전화:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
팩스:
408-969-0336
이메일:
[email protected]
연구 모델
HUGO-Ab™(항체 개발을 위한 인간화 게놈 Ortholog)HUGO-GT™(유전자 치료를 위한 인간화 게놈 Ortholog)MouseAtlas 모델 라이브러리연구용 동물 모델
서비스
신경과학안과학종양학대사 및 심혈관 질환자가면역 및 염증
회사 소개
회사 소개시설 개요동물 건강 및 복지건강 보고서대리점인재채용문의하기
소셜 미디어
면책 조항: Cyagen의 제품 및 서비스 가격과 제공 여부는 지역에 따라 다를 수 있습니다. 명표시된 가격은 특정 국가에만 적용됩니다. 자세한 내용은 Cyagen으로 문의해 주시기 바랍니다.
Copyright © 2025 Cyagen. All rights reserved.
개인정보 처리방침
사이트 맵
Cyagen 최신 소식 받아보기
연구 모델, CRO 서비스, 과학 자료 및 특별 혜택에 대한 최신 소식을 연구 니즈에 맞춰 이메일로 받아보세요.
성명
이메일
조직
관심 분야
주요 연구 분야